Volitionrx Ltd (VNRX) · Oct 27, 2026 · Other events
$500K debt prepayment — $2.4M note reduced to $706,667; $500K paid in cash
VolitionRx’s debt agreement lowers the Lind note to $706,667 and pauses conversion through January, but defers near-term repayments.
Volition is a cash-burning diagnostics developer trying to commercialize Nu.Q blood tests in cancer and sepsis while pursuing licensing deals and reimbursement milestones. Its latest reported figures showed $2.8 million of cash against $10.4 million of six-month operating cash burn, and management said additional funding would be required to continue operations and meet obligations.
| Filing figure | Amount / change | Comparison or condition |
|---|---|---|
| Original Lind note | $2.4 million | Issued January 15, 2026 (Waiver description) |
| Cash partial prepayment | $500,000 | Paid October 23, 2026 (Waiver description) |
| Remaining Lind note | $706,667 | After the prepayment (Press release) |
| Other Lind note | $7.5 million | Fully satisfied in September (Press release) |
| Total debt reduction | Over $5.0 million | Across both notes since June 30, 2026 (Press release) |
| Conversion-rights restriction | Through January 1, 2027 | Unless closing price reaches $0.275 (Waiver description) |
| Deferred repayments | November and December 2026 | Added to outstanding principal (Waiver description) |
The filing materially reduces the most immediate financing overhang. Volition pays $500,000 in cash and brings the $2.4 million Lind note down to $706,667. 〔0〕 The separate $7.5 million Lind note was already retired in September, so this is the next step in a deleveraging effort the market already knew was underway rather than a wholly new strategic turn.
The waiver also lowers near-term conversion and dilution pressure, but it is not a clean cash-flow victory. Lind cannot exercise conversion rights before January 1, 2027 unless the closing price reaches $0.275, reducing the immediate risk that repayment mechanics force additional shares. At the same time, Volition is deferring the November and December repayments rather than eliminating them; those amounts remain part of the principal. 〔1〕
The important tension is liquidity: Volition is using scarce cash to retire debt while still operating far from self-funding. Against the company’s reported cash burn and stated need for additional financing, the $500,000 payment improves the liability profile but consumes cash that could otherwise support testing, commercialization, or operations. The filing therefore advances the balance-sheet cleanup, but does not resolve the underlying funding problem.
Bottom line: This is a modestly favorable financing update: less debt and less immediate conversion risk, but with two repayments pushed out rather than removed. It matters for the capital structure, not yet for Volition’s core commercialization story.
January 1, 2027 conversion-rights reset
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!